Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Novation LLC

Latest From Novation LLC

New Surgical Tool Shines Light On Orthopedic Procedures

Invuity has launched a new illuminated orthopedic surgical tool, adding to its growing line of devices that promise to provide surgeons with improved visibility in an era of smaller and smaller surgical incisions.

Medical Device United States

Heart Failure Devices: Raising Roadblocks To Readmission

A new Medicare cost-control program aimed at reducing costly hospital readmissions has heart failure squarely in the cross-hairs, and the consequences could mean hundreds of thousands of dollars in lost Medicare revenue for hospitals that fail to meet the new readmission standards. As a result, providers are scrambling to implement programs to assess and reduce heart failure readmissions, and a growing number of device companies are touting a variety of technologies they believe could help them achieve that goal.

Medical Device Reimbursement

Changing Form, But Not Function: Smith & Nephew Expands NPWT Market

The drive toward cost-effectiveness and expanded patient access have spurred device developers to take proven therapies or procedures and re-engineer them in ways that make them simpler, less expensive and easier to use. Now, the biggest player in wound care is following suit. In January, Smith & Nephew PLC announced that the FDA had cleared PICO, its new, single-use, pocket-sized negative pressure wound therapy (NPWT) system.

Medical Device

Heart Failure Devices: Raising Roadblocks To Readmission

A new Medicare cost-control program aimed at reducing costly hospital readmissions has heart failure squarely in the cross-hairs, and the consequences could mean hundreds of thousands of dollars in lost Medicare revenue for hospitals that fail to meet the new readmission standards. As a result, providers are scrambling to implement programs to assess and reduce heart failure readmissions, and a growing number of device companies are touting a variety of technologies they believe could help them achieve that goal.

Medical Device Clinical Trials
See All

Company Information

  • Industry
  • Distributors
  • Services
  • Services
    • Hospitals, Nursing Homes, Institutions
UsernamePublicRestriction

Register